Non-motor symptoms in Parkinson's disease

European Neurological Review

Volumn 7, Issue 1, 2012, Pages 35-40

  Uc, Ergun Y ^a   Tippin, Jon ^a   Chou, Kelvin L ^b   Erickson, Bradley A ^a   Doerschug, Kevin C ^a   Jimmeh Fletcher, Decontee M ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Autonomic dysfunction; Cognition; Constipation; Dementia; Parkinson's disease; Vision

Indexed keywords

EID: 84865184561     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2012.07.01.35     Document Type: Article

References (160)

1. Langston JW, The parkinson's complex: Parkinsonism is just the tip of the iceberg, Ann Neurol, 2006;59:591-6.
2. Zesiewicz TA, Sullivan KL, Arnulf I, et al., Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 2010;74:924-31.
3. Chaudhuri KR, Healy DG, Schapira AH, Non-motor symptoms of Parkinson's disease: diagnosis and management, Lancet Neurol, 2006;5:235-45.
4. Visser M, van Rooden SM, Verbaan D, et al., A comprehensive model of health-related quality of life in Parkinson's disease, J Neurol, 2008;255:1580-7.
5. Chaudhuri KR, Schapira AH, Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, Lancet Neurol, 2009;8:464-74.
6. Goldstein DS, Sewell L, Holmes C, Association of anosmia with autonomic failure in Parkinson disease, Neurology, 2010;74:245-51.
7. Braak H, Del Tredici K, Rub U, et al., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 2003;24:197-211.
8. Williams-Gray CH, Foltynie T, Brayne CE, et al., Evolution of cognitive dysfunction in an incident Parkinson's disease cohort, Brain, 2007;130:1787-98.
9. Uc EY, Rizzo M, Anderson SW, et al., Visual dysfunction in Parkinson disease without dementia, Neurology, 2005;65:1907-13.
10. Aarsland D, Bronnick K, Larsen JP, et al., Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study, Neurology, 2009;72:1121-6.
11. Schrag A, Jahanshahi M, Quinn N, What contributes to quality of life in patients with Parkinson's disease?, J Neurol Neurosurg Psychiatry, 2000;69:308-12.
12. Uc EY, Rizzo M, Anderson SW, et al., Impaired visual search in drivers with Parkinson's disease, Ann Neurol, 2006;60:407-13.
13. Uc EY, Rizzo M, Anderson SW, et al., Impaired navigation in drivers with Parkinson's disease, Brain, 2007;130:2433-40.
14. Uc EY, Rizzo M, Anderson SW, et al., Driving under low-contrast visibility conditions in Parkinson disease, Neurology, 2009;73:1103-10.
15. Uc EY, Rizzo M, Johnson AM, et al., Road safety in drivers with Parkinson disease, Neurology, 2009;73:2112-9.
16. Vossius C, Larsen JP, Janvin C, et al., The economic impact of cognitive impairment in Parkinson's disease, Mov Disord, 2011;26:1541-4.
17. Kempster PA, Williams DR, Selikhova M, et al., Patterns of levodopa response in Parkinson's disease: a clinico-pathological study, Brain, 2007;130:2123-8.
18. Buter TC, van den HA, Matthews FE, et al., Dementia and survival in Parkinson disease: a 12-year population study, Neurology, 2008;70:1017-22.
19. Hughes TA, Ross HF, Musa S, et al., A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease, Neurology, 2000;54:1596-602.
20. Levy G, Schupf N, Tang MX, et al., Combined effect of age and severity on the risk of dementia in Parkinson's disease, Ann Neurol, 2002;51:722-9.
21. Aarsland D, Andersen K, Larsen JP, et al., Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study, Arch Neurol, 2003;60:387-92.
22. Hely MA, Reid WG, Adena MA, et al., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years, Mov Disord, 2008;23:837-44.
23. Hobson P, Meara J, Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom, Mov Disord, 2004;19:1043-9.
24. Marder K, Tang MX, Cote L, et al., The frequency and associated risk factors for dementia in patients with Parkinson's disease, Arch Neurol, 1995;52:695-701.
25. Aarsland D, Andersen K, Larsen JP, et al., Risk of dementia in Parkinson's disease: a community-based, prospective study, Neurology, 2001;56:730-6.
26. Litvan I, Aarsland D, Adler CH, et al., MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI, Mov Disord, 2011;26:1814-24.
27. Aarsland D, Bronnick K, Williams-Gray C, et al,. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis, Neurology, 2010;75:1062-9.
28. Aarsland D, Bronnick K, Larsen JP, et al., Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study, Neurology, 2009;72:1121-6.
29. Aarsland D, Bronnick K, Fladby T, Mild cognitive impairment in Parkinson's disease, Curr Neurol Neurosci Rep, 2011;11:371-8.
30. Emre M, Aarsland D, Brown R, et al., Clinical diagnostic criteria for dementia associated with Parkinson's disease, Mov Disord, 2007;22:1689-707.
31. Uc EY, McDermott MP, Marder KS, et al., Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort, Neurology, 2009;73:1469-77.
32. Poewe W, Dysautonomia and cognitive dysfunction in Parkinson's disease, Mov Disord, 2007;22:S374-S378.
33. Cools R, Barker RA, Sahakian BJ, et al., Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands, Cereb Cortex, 2001;11:1136-43.
34. Smeding HM, Speelman JD, Huizenga HM, et al., Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's disease, J Neurol Neurosurg Psychiatry, 2011;82:754-60.
35. Weaver FM, Follett K, Stern M, et al., Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial, JAMA, 2009;301:63-73.
36. Follett KA, Weaver FM, Stern M, et al., Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease, N Engl J Med, 2010;362:2077-91.
37. van LT, De Deyn PP, Aarsland D, et al., Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data, CNS Neurosci Ther, 2011;17:428-41.
38. Emre M, Dementia in Parkinson's disease: cause and treatment, Curr Opin Neurol, 2004;17:399-404.
39. Ravina B, Putt M, Siderowf A, et al., Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study, J Neurol Neurosurg Psychiatry, 2005;76:934-9.
40. Aarsland D, Ballard C, Walker Z, et al., Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial, Lancet Neurol, 2009;8:613-8.
41. Emre M, Tsolaki M, Bonuccelli U, et al., Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial, Lancet Neurol, 2010;9:969-77.
42. Biousse V, Skibell BC, Watts RL, et al., Ophthalmologic features of Parkinson's disease, Neurology, 2004;62:177-80.
43. Oh YS, Kim JS, Chung SW, et al., Color vision in Parkinson's disease and essential tremor, Eur J Neurol, 2011;18:577-83.
44. Sampaio J, Bobrowicz-Campos E, Andre R, et al., Specific impairment of visual spatial covert attention mechanisms in Parkinson's disease, Neuropsychologia, 2011;49:34-42.
45. Rodnitzky RL, Visual dysfunction in Parkinson's disease, Clin Neurosci, 1998;5:102-6.
46. Azulay JP, Mesure S, Amblard B, et al., Visual control of locomotion in Parkinson's disease, Brain, 1999;122(Pt 1):111-20.
47. Donovan S, Lim C, Diaz N, et al., Laserlight cues for gait freezing in Parkinson's disease: an open-label study, Parkinsonism Relat Disord, 2011;17:240-5.
48. Frazzitta G, Maestri R, Uccellini D, et al., Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training, Mov Disord, 2009;24:1139-43.
49. Uc EY, Rizzo M, Johnson AM, et al., Real-life driving outcomes in Parkinson disease, Neurology, 2011;76:1894-902.
50. Aarsland D, Larsen JP, Lim NG, et al., Range of neuropsychiatric disturbances in patients with Parkinson's disease, J Neurol Neurosurg Psychiatry, 1999;67:492-6.
51. Schrag A, Barone P, Brown RG, et al., Depression rating scales in Parkinson's disease: critique and recommendations, Mov Disord, 2007;22:1077-92.
52. Reijnders JS, Ehrt, U, Weber WE, et al., A systematic review of prevalence studies of depression in Parkinson's disease, Mov Disord, 2008;23:183-9.
53. Tandberg E, Larsen JP, Aarsland D, et al., The occurrence of depression in Parkinson's disease. A community-based study, Arch Neurol, 1996;53:175-9.
54. Dissanayaka NN, Sellbach A, Silburn PA, et al., Factors associated with depression in Parkinson's disease, J Affect Disord, 2011;132:82-8.
55. Leentjens AF, Lousberg R, Verhey FR, Markers for depression in Parkinson's disease, Acta Psychiatr Scand, 2002;106:196-201.
56. Devos D, Dujardin K, Poirot I, et al., Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study, Mov Disord, 2008;23:850-7.
57. Menza M, Dobkin RD, Marin H, et al., A controlled trial of antidepressants in patients with Parkinson disease and depression, Neurology, 2009;72:886-92.
58. Chen P, Kales HC, Weintraub D, et al., Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample, J Geriatr Psychiatry Neurol, 2007;20:161-5.
59. Barone P, Poewe W, Albrecht S, et al., Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial, Lancet Neurol, 2010;9:573-80.
60. Pontone GM, Williams JR, Anderson KE, et al., Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease, Mov Disord, 2009;24:1333-8.
61. Leentjens AF, Dujardin K, Marsh L, et al., Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale, Mov Disord, 2011;26:407-15.
62. Witjas T, Kaphan E, Azulay JP, et al., Nonmotor fluctuations in Parkinson's disease: frequent and disabling, Neurology, 2002;59:408-13.
63. Fenelon G, Mahieux F, Huon R, et al., Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors, Brain, 2000;123(Pt 4):733-45.
64. Chou KL, Fernandez HH, Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs, Expert Opin Investig Drugs, 2006;15:339-49.
65. Chou KL, Messing S, Oakes D, et al., Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments, Clin Neuropharmacol, 2005;28:215-9.
66. Barnes J, David AS, Visual hallucinations in Parkinson's disease: a review and phenomenological survey, J Neurol Neurosurg Psychiatry, 2001;70:727-33.
67. Miyasaki JM, Shannon K, Voon V, et al., Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 2006;66:996-1002.
68. Weintraub D, Koester J, Potenza MN, et al., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients, Arch Neurol, 2010;67:589-95.
69. Voon V, Sohr M, Lang AE, et al., Impulse control disorders in Parkinson disease: a multicenter case-control study, Ann Neurol, 2011;69:986-96.
70. Cools R, Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease, Neurosci Biobehav Rev, 2006;30:1-23.
71. Ardouin C, Voon V, Worbe Y, et al., Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation, Mov Disord, 2006;21:1941-6.
72. Smeding HM, Goudriaan AE, Foncke EM, et al., Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease, J Neurol Neurosurg Psychiatry, 2007;78:517-9.
73. Thomas A, Bonanni L, Gambi F, et al., Pathological gambling in Parkinson disease is reduced by amantadine, Ann Neurol, 2010;68:400-4.
74. Kirsch-Darrow L, Fernandez HH, Marsiske M, et al., Dissociating apathy and depression in Parkinson disease, Neurology, 2006;67:33-8.
75. Pedersen KF, Alves G, Aarsland D, et al., Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study, J Neurol Neurosurg Psychiatry, 2009;80:1279-82.
76. Kirsch-Darrow L, Zahodne LB, Marsiske M, et al., The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease, Parkinsonism Relat Disord, 2011;17:182-8.
77. Savica R, Carlin JM, Grossardt BR, et al., Medical records documentation of constipation preceding Parkinson disease: A case-control study, Neurology, 2009;73:1752-8.
78. Krogh K, Ostergaard K, Sabroe S, et al., Clinical aspects of bowel symptoms in Parkinson's disease, Acta Neurol Scand, 2008;117:60-4.
79. Wang G, Wan Y, Cheng Q, et al., Malnutrition and associated factors in Chinese patients with Parkinson's disease: Results from a pilot investigation, Parkinsonism Relat Disord, 2010;16:119-23.
80. Goetze O, Nikodem AB, Wiezcorek J, et al., Predictors of gastric emptying in Parkinson's disease, Neurogastroenterol Motil, 2006;18:369-75.
81. Goetze O, Wieczorek J, Mueller T, et al., Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13Csodium octanoate breath test, Neurosci Lett, 2005;375:170-3.
82. Krygowska-Wajs A, Cheshire WP, Jr, Wszolek ZK, et al., Evaluation of gastric emptying in familial and sporadic Parkinson disease, Parkinsonism Relat Disord, 2009;15:692-6.
83. Jost WH, Gastrointestinal dysfunction in Parkinson's disease, J Neurol Sci, 2010;289:69-73.
84. Lebouvier T, Chaumette T, Damier P, et al., Pathological lesions in colonic biopsies during Parkinson's disease, Gut, 2008;57:1741-3.
85. Petrovitch H, Abbott RD, Ross GW, et al., Bowel movement frequency in late-life and substantia nigra neuron density at death, Mov Disord, 2008;24:371-6.
86. Taylor TN, Caudle WM, Shepherd KR, et al., Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity, J Neurosci, 2009;29:8103-13.
87. Kuo YM, Li, Z, Jiao Y, et al., Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes, Hum Mol Genet, 2010;19:1633-50.
88. Chaumette T, Lebouvier T, Aubert P, et al., Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism, Neurogastroenterol Motil, 2009;21:215-22.
89. Blandini F, Balestra B, Levandis G, et al., Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease, Neurosci Lett, 2009;467:203-7.
90. Greene JG, Noorian AR, Srinivasan S, Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease, Exp Neurol, 2009;218:154-61.
91. Drolet RE, Cannon JR, Montero L, et al., Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology, Neurobiol Dis, 2009;36:96-102.
92. Morgan JC, Sethi KD, Tegaserod in constipation associated with Parkinson disease, Clin Neuropharmacol, 2007;30:52-4.
93. Sullivan KL, Staffetti JF, Hauser RA, et al., Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease, Mov Disord, 2006;21:115-6.
94. Zangaglia R, Martignoni E, Glorioso M, et al., Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study, Mov Disord, 2007;22:1239-44.
95. Zibetti M, Torre E, Cinquepalmi A, et al., Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus, Eur Neurol, 2007;58:218-23.
96. Asai H, Udaka F, Hirano M, et al., Increased gastric motility during 5-HT(4) agonist therapy reduces response fluctuations in Parkinson's disease, Parkinsonism Relat Disord, 2005;11:499-502.
97. Adhiyaman V, Hobson P, Meara RJ, Central and peripheral autonomic integrity in Parkinson's disease, Age Ageing, 2008;37:578-81.
98. Pandya M, Kubu CS, Giroux ML, Parkinson disease: not just a movement disorder, Cleve Clin J Med, 2008;75:856-64.
99. Goldstein DS, Holmes CS, Dendi R, et al., Orthostatic hypotension from sympathetic denervation in Parkinson's disease, Neurology, 2002;58:1247-55.
100. Senard JM, Chamontin B, Rascol A, et al., Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension, Clin Auton Res, 1992;2:99-104.
101. Araki I, Kuno S, Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score, J Neurol Neurosurg Psychiatry, 2000;68:429-33.
102. Winge K, Skau AM, Stimpel H, et al., Prevalence of bladder dysfunction in Parkinsons disease, Neurourol Urodyn, 2006;25:116-22.
103. Winge K, Nielsen KK, Stimpel H, et al., Lower urinary tract symptoms and bladder control in advanced Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus, Mov Disord, 2007;22:220-5.
104. Sakakibara R, Uchiyama T, Yamanishi T, et al., Genitourinary dysfunction in Parkinson's disease, Mov Disord, 2010;25:2-12.
105. Blackett H, Walker R, Wood B, Urinary dysfunction in Parkinson's disease: a review, Parkinsonism Relat Disord, 2009;15:81-7.
106. Seif C, Herzog J, van der HC, et al., Effect of subthalamic deep brain stimulation on the function of the urinary bladder, Ann Neurol, 2004;55:118-20.
107. Winge K, Friberg L, Werdelin L, et al., Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease, Eur J Neurol, 2005;12:842-50.
108. Hineno T, Mizobuchi M, Hiratani K, et al., Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs, Brain Res, 1992;580:92-9.
109. Menza M, Dobkin RD, Marin H, et al., Sleep disturbances in Parkinson's disease, Mov Disord, 2010;25(Suppl. 1):S117-S22.
110. Sakakibara R, Hattori T, Uchiyama T, et al., Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy, J Neurol Neurosurg Psychiatry, 2001;71:600-6.
111. Bennett N, O'Leary M, Patel AS, et al., Can higher doses of oxybutynin improve efficacy in neurogenic bladder?, J Urol, 2004;171:749-51.
112. Ehrt U, Broich K, Larsen JP, et al., Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study, J Neurol Neurosurg Psychiatry, 2010;81:160-5.
113. Cooper JA, Sagar HJ, Doherty SM, et al., Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients, Brain, 1992;115(Pt 6):1701-25.
114. Andersson KE, Treatment of overactive bladder: other drug mechanisms, Urology, 2000;55:51-7.
115. Giannantoni A, Rossi A, Mearini E, et al., Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy, J Urol, 2009;182:1453-7.
116. Neu HC, Connolly JJ Jr, Schwertley FW, et al., Obstructive respiratory dysfunction in parkinsonian patients, Am Rev Respir Dis, 1967;95:33-47.
117. Estenne M, Hubert M, De Troyer A, Respiratory-muscle involvement in Parkinson's disease, N Engl J Med, 1984;311:1516-7.
118. Canning CG, Alison JA, Allen NE, et al., Parkinson's disease: an investigation of exercise capacity, respiratory function, and gait, Arch Phys Med Rehabil, 1997;78:199-207.
119. Pitts T, Bolser D, Rosenbek J, et al., Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease, Chest, 2009;135:1301-8.
120. Troche MS, Okun MS, Rosenbek JC, et al., Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial, Neurology, 2010;75:1912-9.
121. Schiermeier S, Schafer D, Schafer T, et al., Breathing and locomotion in patients with Parkinson's disease, Pflugers Arch, 2001;443:67-71.
122. Reuter I, Engelhardt M, Freiwaldt J, et al., Exercise test in Parkinson's disease, Clin Auton Res, 1999;9:129-34.
123. Tandberg E, Larsen JP, Karlsen K, A community-based study of sleep disorders in patients with Parkinson's disease, Mov Disord, 1998;13:895-9.
124. Porter B, Macfarlane R, Walker R, The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease, Eur J Neurol, 2008;15:50-4.
125. Comella CL, Sleep disturbances in Parkinson's disease, Curr Neurol Neurosci Rep, 2003;3:173-80.
126. Askenasy JJ, Yahr MD, Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study, Neurology, 1985;35:527-32.
127. Cicolin A, Lopiano L, Zibetti M, et al., Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients, Sleep Med, 2004;5:207-10.
128. Comella CL, Morrissey M, Janko K, Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy, Neurology, 2005;64:1450-1.
129. Suzuki K, Okuma Y, Hattori N, et al., Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A study using Parkinson's disease sleep scale, Mov Disord, 2007;22:1245-51.
130. Garcia-Borreguero D, Odin P, Serrano C, Restless legs syndrome and PD: a review of the evidence for a possible association, Neurology, 2003;61:S49-S55.
131. Happe S, Trenkwalder C, Movement disorders in sleep: Parkinson's disease and restless legs syndrome, Biomed Tech (Berl), 2003;48:62-7.
132. Pittock SJ, Joyce C, O'Keane V, et al., Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred, Neurology, 2000;55:991-5.
133. Maria B, Sophia S, Michalis M, et al., Sleep breathing disorders in patients with idiopathic Parkinson's disease, Respir Med, 2003;97:1151-7.
134. Trotti LM, Bliwise DL, No increased risk of obstructive sleep apnea in Parkinson's disease, Mov Disord, 2010;25:2246-9.
135. Punjabi NM, The epidemiology of adult obstructive sleep apnea, Proc Am Thorac Soc, 2008;5:136-43.
136. Arnulf I, Leu-Semenescu S, Sleepiness in Parkinson's disease, Parkinsonism Relat Disord, 2009;15(Suppl. 3):S101-S4.
137. Gjerstad MD, Aarsland D, Larsen JP, Development of daytime somnolence over time in Parkinson's disease, Neurology, 2002;58:1544-6.
138. Suzuki K, Miyamoto T, Miyamoto M, et al., Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease, J Neurol Sci, 2008;271:47-52.
139. Kaynak D, Kiziltan G, Kaynak H, et al., Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment, Eur J Neurol, 2005;12:199-207.
140. Stevens S, Cormella CL, Stepanski EJ, Daytime sleepiness and alertness in patients with Parkinson disease, Sleep, 2004;27:967-72.
141. Arnulf I, Leu S, Oudiette D, Abnormal sleep and sleepiness in Parkinson's disease, Curr Opin Neurol, 2008;21:472-7.
142. Ondo WG, Fayle R, Atassi F, et al., Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial, J Neurol Neurosurg Psychiatry, 2005;76:1636-9.
143. Meindorfner C, Korner Y, Moller JC, et al., Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel, Mov Disord, 2005;20:832-42.
144. Gagnon JF, Bedard MA, Fantini ML, et al., REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease, Neurology, 2002;59:585-9.
145. Claassen DO, Josephs KA, Ahlskog JE, et al., REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century, Neurology, 2010;75:494-9.
146. Boeve BF, Silber MH, Ferman TJ, Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients, Sleep Med, 2003;4:281-4.
147. Ringman JM, Simmons JH, Treatment of REM sleep behavior disorder with donepezil: a report of three cases, Neurology, 2000;55:870-1.
148. Schmidt MH, Koshal VB, Schmidt HS, Use of pramipexole in REM sleep behavior disorder: results from a case series, Sleep Med, 2006;7:418-23.
149. Schenck CH, Mahowald MW, Kim SW, et al., Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder, Sleep, 1992;15:226-35.
150. Fiszer U, Michalowska M, Baranowska B, et al., Leptin and ghrelin concentrations and weight loss in Parkinson's disease, Acta Neurol Scand, 2010;121:230-6.
151. Delikanaki-Skaribas E, Trail M, Wong WW, et al., Daily energy expenditure, physical activity, and weight loss in Parkinson's disease patients, Mov Disord, 2009;24:667-71.
152. Aziz NA, van der Marck MA, Pijl H, et al., Weight loss in neurodegenerative disorders, J Neurol, 2008;255:1872-80.
153. Uc EY, Struck LK, Rodnitzky RL, et al., Predictors of weight loss in Parkinson's disease, Mov Disord, 2006;21:930-6.
154. Chen H, Zhang SM, Hernan MA, et al., Weight loss in Parkinson's disease, Ann Neurol, 2003;53:676-9.
155. Lorefalt B, Ganowiak W, Palhagen S, et al., Factors of importance for weight loss in elderly patients with Parkinson's disease, Acta Neurol Scand, 2004;110:180-7.
156. Strowd RE, Cartwright MS, Passmore LV, et al., Weight change following deep brain stimulation for movement disorders, J Neurol, 2010;257:1293-7.
157. Walker HC, Lyerly M, Cutter G, et al., Weight changes associated with unilateral STN DBS and advanced PD, Parkinsonism Relat Disord, 2009;15:709-11.
158. Wszolek ZK, Markopoulou K, Olfactory dysfunction in Parkinson's disease, Clin Neurosci, 1998;5:94-101.
159. Bohnen NI, Muller ML, Kotagal V, et al., Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease, Brain, 2010;133:1747-54.
160. Chaudhuri KR, Odin P, Antonini A, et al., Parkinson's disease: The non-motor issues, Parkinsonism Relat Disord, 2011;17:717-23.